NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Systematix Research Report
We value Sastasundar Ventures Ltd. at 35 times FY26E Ebitda to arrive at a target price of Rs 596. Our Buy on Sastasundar Ventures as a preferred play on the ongoing supply chain consolidation in the pharmaceutical space stems from-
large revenue expansion opportunity,
scope for significant margin expansion,
strong execution track record,
expected strong return profile of the business,
a strong balance sheet - 25% stake in Flipkart health, and
a strong net cash position to support its growth plans.
Sastasundar Ventures is seeking profitable growth, and is therefore cautiously deploying capital. This has not constrained its growth momentum, evident from the 40% compound annual growth rate in its revenue over the last three years.
Risks
Adverse regulation impacting sales of online pharmacies,
Execution delays – Slowdown in ramp up of Retailshakti,
Higher working capital investments than envisaged could dilute its return on capital employed meaningfully.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
